http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1993060

Outgoing Links

Predicate Object
contentType Journal Article
endingPage e289
issn 1470-2045
issueIdentifier 7
pageRange e288-e289
publicationName The Lancet. Oncology
startingPage e288
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c38bbe1868db96f9b066514ecff81161
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_28903d13bea95bb3bfaed69b3fc2049a
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_0071671e0d5c2067c0c3bc602c6c15de
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_4788fa66c0f72459bbecbd3833da3c9b
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_68bcc4ee3ecb0b8328760b136f34d8cd
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_6b181f030ebe017706f6db04f81d8fc5
bibliographicCitation Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply. Lancet Oncol. 2021 Jul;22(7):e288–9. doi: 10.1016/s1470-2045(21)00341-7. PMID: 34197751.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_28c67dc3e686b607a404d0cfd10075f8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a8d013cb55d4defa7956a673cb273e65
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3b49d043a6bc16b1dc40a4a1e969fcc9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ad8c64224ef899b0bcc5b3268625e247
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-4824-6600
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9c78d9ae2f807d568e54450e6a5ad6d2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5f7d68807f9b53abf412fdbe075012e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e6833bc58b515eb8f67b7a2994cc89bf
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3a4aa82ed6407b3865e554a0d4a7452c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-9696-6122
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31e22146a7a30fc9e05c0482d5eb0d97
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9a71320eaecb8ab360e5c37ac5dc4eb6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1dbb08244d25a4e9213ab77f68c4620c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2095e8adb48614fc3f12cec64f7d770a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9b1aa4aa69ed46f19e82304022616963
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_583b7f40144b3dac0a5f2f01e41cfcdd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_57392c38695e7f529f5bd0a7b0ab893f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cf19466fa49a8604b3b318a95ac6ac0d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f4bc5f10f69eab48e61ca655bb29b1e6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_739a2ec2d1d0a3cc7dfa795e41668428
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_432125769965b7769a11f7f62e8b8e91
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_179ddb98d70a83b26d29b190ab800478
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eea0f387b62f9690c7454fc7727d6f59
date 202107
identifier https://doi.org/10.1016/s1470-2045%2821%2900341-7
https://pubmed.ncbi.nlm.nih.gov/34197751
isPartOf https://portal.issn.org/resource/ISSN/1470-2045
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply
discusses http://id.nlm.nih.gov/mesh/M0004519
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D001661Q000188
http://id.nlm.nih.gov/mesh/D001650
hasSubjectTerm http://id.nlm.nih.gov/mesh/D002955Q000009
http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135659064
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7039

Showing number of triples: 1 to 53 of 53.